Kytopen on February 07, 2023

MIT News: 3 Questions: Cullen Buie on a new era for cell therapies

Read the original post on MIT News


The associate professor of MechE reflects on how his company, Kytopen, has grown and shifted focus in developing safer immunotherapies.
Photo of a man in a shortsleeve button-down shirt sitting in a lab with his hands folded, looking at the camera
CaptionAssociate Professor Cullen Buie
CreditsPhoto courtesy of The Engine.


Genetic engineering and personalized cell therapies could transform health care. In recent years, stem cells and gene-editing tools like CRISPR have been making headlines for the possibilities they offer to treat diseases, including cancer. But engineering cells is a slow, labor-intensive process, making it difficult to produce personalized therapies at scale.

The startup Kytopen, co-founded by MIT Associate Professor Cullen Buie and former MIT postdoc and research scientist Paolo Garcia, offers a solution that could lead to the mass production of genetically engineered cells. Here, Buie answers some questions about how Kytopen has grown since its founding.

Read the Q+A >>